Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Generated: May 29, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,156,331

« Back to Dashboard

Which drugs does patent 6,156,331 protect, and when does it expire?


Patent 6,156,331 protects VIADUR and is included in one NDA.

This patent has seventy-seven patent family members in twenty-nine countries.

Summary for Patent: 6,156,331

Title: Sustained delivery of an active agent using an implantable system
Abstract:The invention is directed to a device for delivering an active agent formulation for a predetermined administration period. An impermeable reservoir is divided into a water-swellable agent chamber and an active agent formulation chamber. Fluid from the environment is imbibed through a semipermeable plug into the water-swellable agent chamber and the active agent formulation is released through a back-diffusion regulating outlet. Delivery periods of up to 2 years are achieved.
Inventor(s): Peery; John R. (Stanford, CA), Dionne; Keith E. (Menlo Park, CA), Eckenhoff, deceased; James B. (late of Los Altos, CA), Landrau; Felix A. (Punta Gorda, FL), Lautenbach; Scott D. (San Mateo, CA), Magruder; Judy A (Mountain View, CA), Wright; Jeremy C. (Los Altos, CA)
Assignee: ALZA Corporation (Mountain View, CA)
Application Number:09/310,149
Patent Claim Types:
see list of patent claims
Delivery; Device;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Ortho Mcneil Janssen
VIADUR
leuprolide acetate
IMPLANT;IMPLANTATION021088-001Mar 3, 2000DISCNNoNo6,156,331► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 6,156,331

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,132,420 Osmotic delivery system and method for enhancing start-up and performance of osmotic delivery systems► Subscribe
5,728,396 Sustained delivery of leuprolide using an implantable system► Subscribe
8,535,701Sustained delivery of an active agent using an implantable system► Subscribe
6,635,268 Sustained delivery of an active agent using an implantable system► Subscribe
8,298,562Sustained delivery of an active agent using an implantable system► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,156,331

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office1249229► Subscribe
European Patent Office1238660► Subscribe
European Patent Office1238659► Subscribe
European Patent Office1238658► Subscribe
European Patent Office1238657► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot